Syndax Pharmaceuticals (SNDX) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

SNDX Syndax Pharmaceuticals

Watchlist

15.570
+0.330+2.17%

Close Feb 26 16:00 ET

14.830
-0.740-4.75%

Pre 05:37 ET

1.33BMarket Cap-4.28P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Earnings Preview: SNDX to Report Financial Results Pre-market on March 03
Moomoo NewsFeb 26 02:00 ET
Syndax Announces Participation in March Investor Conferences
GlobeNewswireFeb 25 07:00 ET
Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025
GlobeNewswireFeb 24 07:00 ET
Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm
newsfileFeb 17 17:41 ET
Have Syndax Pharmaceuticals Insiders Been Selling Stock?
Simply Wall StFeb 15 07:13 ET
Express News | Syndax Pharmaceuticals Inc : Guggenheim Cuts Target Price to $32 From $35
ReutersFeb 13 06:49 ET

Comments

Trytosaveabit

Dec 9, 2024 06:45

Update

$Syndax Pharmaceuticals (SNDX.US)$ Reuters· 11 mins ago
Syndax Pharmaceuticals: Subgroup Analyses From Ph 2 Protocol-Defined R/R Mnpm1 Aml Efficacy Population Show Responses Across All Major Subgroups

Jaguar8

Nov 17, 2024 13:32

J.P. Morgan analyst has maintained their bullish stance on stock, giving a Buy rating on November 13. Goldman Sachs give it price target $31.

$Syndax Pharmaceuticals (SNDX.US)$

Jaguar8

Nov 16, 2024 16:41

My watchlist Monday. Why? FDA approval- first of its kind for acute adult and pediatric leukemia

$Syndax Pharmaceuticals (SNDX.US)$

Trytosaveabit

Nov 15, 2024 18:07

Repost of FDA approval! Longer PR because to me this seems like a pretty big deal? More so than most approvals! JMO

$Syndax Pharmaceuticals (SNDX.US)$ But im sure/hoping Dr @Jaguar8 will either confirm or dispute! To me seems pretty AWESOME! ((((((. Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
1 HOUR AGO, 5:29 PM EST
VIA PR NEWSWIRE
– Approva...

Jaguar8

Nov 15, 2024 16:32

NEWS RECAP

$Syndax Pharmaceuticals (SNDX.US)$
Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation

SNDX Syndax Pharmaceuticals

Trade Overview

Capital Trend

News

Comments

Trending Stocks